SEC Comment Letter 0000000000-24-005439 to Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc.
Date: May 13, 2024 · CIK: 0002012593 · Accession: 0000000000-24-005439
AI Filing Summary & Sentiment
Reasoning
Letter
United States securities and exchange commission logo May 13, 2024 Troy Ignelzi Chief Financial Officer Rapport Therapeutics, Inc. 1325 Boylston Street, Suite 401 Boston, MA 02215 Re:Rapport Therapeutics, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted April 29, 2024 CIK No. 0002012593 Dear Troy Ignelzi: We have reviewed your amended draft registration statement and have the following comments. Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing the information you provide in response to this letter and your amended draft registration statement or filed registration statement, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our April 24, 2024 letter. Amendment No. 1 to Draft Registration Statement submitted April 29, 2024 Introduction to RAP-219, page 4 1.We note your revised disclosure on page 5 and elsewhere in response to prior comment 1. With reference to the second full sentence on page 5, and with a view to clarified disclosure, please tell us whether there is preclinical data demonstrating that RAP-219 has minimal or no expression in the cerebellum, brainstem and other brain areas that are critical for normal brain functions. In this regard, we note that the preclinical study presented on page 121 appears to have been conducted using a molecule that is not RAP- 219.
FirstName LastNameTroy Ignelzi Comapany NameRapport Therapeutics, Inc. May 13, 2024 Page 2 FirstName LastName Troy Ignelzi Rapport Therapeutics, Inc. May 13, 2024 Page 2 RAP-219 Preclinical Studies, page 121 2.We note your revised disclosure in response to prior comment 7. Please revise to explain whether these other TARPy8 NAMS are third-party molecules or proprietary ones and why preclinical testing was conducted on these molecules and not on RAP-219. To the extent that any of the preclinical data presented relates to RAP-482, please identify the preclinical study and revise the disclosure on page 19 to discuss the reason(s) why RAP- 482 received a full clinical hold from the FDA. Please contact Jenn Do at 202-551-3743 or Daniel Gordon at 202-551-3486 if you have questions regarding comments on the financial statements and related matters. Please contact Tamika Sheppard at 202-551-8346 or Joe McCann at 202-551-6262 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Justin Platt
Show Raw Text
United States securities and exchange commission logo
May 13, 2024
Troy Ignelzi
Chief Financial Officer
Rapport Therapeutics, Inc.
1325 Boylston Street, Suite 401
Boston, MA 02215
Re:Rapport Therapeutics, Inc.
Amendment No. 1 to Draft Registration Statement on Form S-1
Submitted April 29, 2024
CIK No. 0002012593
Dear Troy Ignelzi:
We have reviewed your amended draft registration statement and have the following
comments.
Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR. If you do not believe a comment applies to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
After reviewing the information you provide in response to this letter and your amended
draft registration statement or filed registration statement, we may have additional
comments. Unless we note otherwise, any references to prior comments are to comments in our
April 24, 2024 letter.
Amendment No. 1 to Draft Registration Statement submitted April 29, 2024
Introduction to RAP-219, page 4
1.We note your revised disclosure on page 5 and elsewhere in response to prior comment
1. With reference to the second full sentence on page 5, and with a view to clarified
disclosure, please tell us whether there is preclinical data demonstrating that RAP-219 has
minimal or no expression in the cerebellum, brainstem and other brain areas that are
critical for normal brain functions. In this regard, we note that the preclinical study
presented on page 121 appears to have been conducted using a molecule that is not RAP-
219.
FirstName LastNameTroy Ignelzi
Comapany NameRapport Therapeutics, Inc.
May 13, 2024 Page 2
FirstName LastName
Troy Ignelzi
Rapport Therapeutics, Inc.
May 13, 2024
Page 2
RAP-219 Preclinical Studies, page 121
2.We note your revised disclosure in response to prior comment 7. Please revise to explain
whether these other TARPy8 NAMS are third-party molecules or proprietary ones and
why preclinical testing was conducted on these molecules and not on RAP-219. To the
extent that any of the preclinical data presented relates to RAP-482, please identify the
preclinical study and revise the disclosure on page 19 to discuss the reason(s) why RAP-
482 received a full clinical hold from the FDA.
Please contact Jenn Do at 202-551-3743 or Daniel Gordon at 202-551-3486 if you have
questions regarding comments on the financial statements and related matters. Please contact
Tamika Sheppard at 202-551-8346 or Joe McCann at 202-551-6262 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Justin Platt